Positive News SentimentPositive NewsNASDAQ:GNTA Genenta Science (GNTA) Stock Price, News & Analysis $3.54 +0.05 (+1.58%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Genenta Science Stock (NASDAQ:GNTA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Genenta Science alerts:Sign Up Key Stats Today's Range$3.51▼$3.6050-Day Range$3.05▼$3.9852-Week Range$2.74▼$7.28Volume1,370 shsAverage Volume5,984 shsMarket Capitalization$64.38 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingBuy Company Overview Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy. Read More Genenta Science Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreGNTA MarketRank™: Genenta Science scored higher than 56% of companies evaluated by MarketBeat, and ranked 720th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGenenta Science has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenenta Science has received no research coverage in the past 90 days.Read more about Genenta Science's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Genenta Science are expected to decrease in the coming year, from ($0.93) to ($1.07) per share.Price to Book Value per Share RatioGenenta Science has a P/B Ratio of 4.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.05% of the float of Genenta Science has been sold short.Short Interest Ratio / Days to CoverGenenta Science has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genenta Science has recently increased by 1.52%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenenta Science does not currently pay a dividend.Dividend GrowthGenenta Science does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.05% of the float of Genenta Science has been sold short.Short Interest Ratio / Days to CoverGenenta Science has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genenta Science has recently increased by 1.52%, indicating that investor sentiment is decreasing. News and Social Media3.8 / 5News SentimentN/A News SentimentGenenta Science has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Genenta Science this week, compared to 0 articles on an average week.Search Interest1 people have searched for GNTA on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genenta Science insiders have not sold or bought any company stock.Percentage Held by Insiders28.99% of the stock of Genenta Science is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.13% of the stock of Genenta Science is held by institutions.Read more about Genenta Science's insider trading history. Receive GNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genenta Science and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNTA Stock News HeadlinesGenenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival SignalsJuly 1, 2025 | globenewswire.comGNTA Genenta Science S.p.A.May 30, 2025 | seekingalpha.com“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 26 at 2:00 AM | Weiss Ratings (Ad)Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapiesMay 7, 2025 | globenewswire.comGenenta Showcases Strategic Vision at Premier Biotech Forum in QatarApril 15, 2025 | globenewswire.comGenenta Science announces EUR 20M financing to expand pipelineMarch 21, 2025 | markets.businessinsider.comGenenta Science Secures €20 Million Convertible Bond Financing for Oncology ResearchMarch 19, 2025 | tipranks.comGenenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival RatesMarch 19, 2025 | globenewswire.comSee More Headlines GNTA Stock Analysis - Frequently Asked Questions How have GNTA shares performed this year? Genenta Science's stock was trading at $4.35 at the beginning of 2025. Since then, GNTA shares have decreased by 19.1% and is now trading at $3.52. When did Genenta Science IPO? Genenta Science (GNTA) raised $28 million in an initial public offering on Wednesday, December 15th 2021. The company issued 2,400,000 shares at $10.50-$12.50 per share. How do I buy shares of Genenta Science? Shares of GNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Genenta Science own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genenta Science investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), PDD (PDD) and AppLovin (APP). Company Calendar Today8/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GNTA CIK1838716 Webwww.genenta.com Phone39-02-2643-4681FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Price Target for Genenta Science$25.00 High Price Target$25.00 Low Price Target$25.00 Potential Upside/Downside+615.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.89 Quick Ratio6.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book4.72Miscellaneous Outstanding Shares18,290,000Free Float12,988,000Market Cap$63.92 million OptionableNot Optionable Beta0.62 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:GNTA) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s national nightmare is hereTop analysts are calling the AI boom “an existential race” — and Washington is going all in. Trillions are bei...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.